Abstract

With over 600 reviews, Transient Receptor Potential (TRP) channels arguably represent today’s most extensively reviewed pharmacological targets. The literature on TRP channels is vast and still growing: it has exploded from a mere 21 papers in 1995 to over 2,000 in the past two years. In the past fifteen years, the field had shown spectacular progress. From the cloning of the vanilloid (capsaicin) recep a novel class of analgesic agents.tor TRPV1 in 1997 it has taken only a decade for the first small molecule TRPV1 antagonists to enter clinical trials as So why to add another review collection to this already overwhelming body of literature? First, new therapeutic tar-gets are emerging (e.g. TRPA1 and TRPV3) that look even more promising than TRPV1. Second, even the most studied TRP channel, TRPV1, continues to surprise. One might ar-gue that we are still at the beginning of the long and arduous road to obtain clinically useful analgesic drugs targeting TRP channels. It remains to be discovered if TRP channels are really Targets for Pain Relief, but it has already been clear that Bernd Nilius was right in calling TRP channels “Truly Remarkable Proteins.”

Highlights

  • Why to add another review collection to this already overwhelming body of literature? First, new therapeutic targets are emerging (e.g. TRPA1 and TRPV3) that look even more promising than TRPV1

  • One might argue that we are still at the beginning of the long and arduous road to obtain clinically useful analgesic drugs targeting Transient Receptor Potential (TRP) channels. It remains to be discovered if TRP channels are really Targets for Pain Relief, but it has already been clear that Bernd Nilius was right in calling TRP channels “Truly Remarkable Proteins.”

  • Licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited

Read more

Summary

Introduction

Why to add another review collection to this already overwhelming body of literature? First, new therapeutic targets are emerging (e.g. TRPA1 and TRPV3) that look even more promising than TRPV1. The Open Pain Journal, 2013, 6, (Suppl 1: M1) 7 Monmouth Medical Center, Long Branch, NJ, USA

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.